266 related articles for article (PubMed ID: 21775441)
1. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).
Garcia-Perez J; Rueda P; Alcami J; Rognan D; Arenzana-Seisdedos F; Lagane B; Kellenberger E
J Biol Chem; 2011 Sep; 286(38):33409-21. PubMed ID: 21775441
[TBL] [Abstract][Full Text] [Related]
2. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
[TBL] [Abstract][Full Text] [Related]
3. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
[TBL] [Abstract][Full Text] [Related]
4. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.
Swinney DC; Beavis P; Chuang KT; Zheng Y; Lee I; Gee P; Deval J; Rotstein DM; Dioszegi M; Ravendran P; Zhang J; Sankuratri S; Kondru R; Vauquelin G
Br J Pharmacol; 2014 Jul; 171(14):3364-75. PubMed ID: 24628038
[TBL] [Abstract][Full Text] [Related]
5. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
[TBL] [Abstract][Full Text] [Related]
6. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
7. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
[TBL] [Abstract][Full Text] [Related]
8. Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.
Latinovic O; Schneider K; Szmacinski H; Lakowicz JR; Heredia A; Redfield RR
Antiviral Res; 2014 Dec; 112():80-90. PubMed ID: 25453341
[TBL] [Abstract][Full Text] [Related]
9. Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study.
Kothandan G; Gadhe CG; Cho SJ
PLoS One; 2012; 7(3):e32864. PubMed ID: 22479344
[TBL] [Abstract][Full Text] [Related]
10. Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop.
Tamamis P; Floudas CA
PLoS One; 2014; 9(4):e95767. PubMed ID: 24763408
[TBL] [Abstract][Full Text] [Related]
11. Modeling the allosteric modulation of CCR5 function by Maraviroc.
Lagane B; Garcia-Perez J; Kellenberger E
Drug Discov Today Technol; 2013; 10(2):e297-305. PubMed ID: 24050281
[TBL] [Abstract][Full Text] [Related]
12. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
Nedellec R; Coetzer M; Lederman MM; Offord RE; Hartley O; Mosier DE
PLoS One; 2011; 6(7):e22020. PubMed ID: 21760945
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism of Action for Allosteric Modulators and Agonists in CC-chemokine Receptor 5 (CCR5).
Karlshøj S; Amarandi RM; Larsen O; Daugvilaite V; Steen A; Brvar M; Pui A; Frimurer TM; Ulven T; Rosenkilde MM
J Biol Chem; 2016 Dec; 291(52):26860-26874. PubMed ID: 27834679
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
[TBL] [Abstract][Full Text] [Related]
15. Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor.
Abrol R; Trzaskowski B; Goddard WA; Nesterov A; Olave I; Irons C
Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13040-5. PubMed ID: 25157173
[TBL] [Abstract][Full Text] [Related]
16. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
[TBL] [Abstract][Full Text] [Related]
17. Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5.
Appiah-Kubi P; Iwuchukwu EA; Soliman MES
J Biomol Struct Dyn; 2022; 40(23):13115-13126. PubMed ID: 34569417
[TBL] [Abstract][Full Text] [Related]
18. Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis.
Moonsamy S; Dash RC; Soliman ME
Molecules; 2014 Apr; 19(4):5243-65. PubMed ID: 24762964
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.
Maeda K; Das D; Yin PD; Tsuchiya K; Ogata-Aoki H; Nakata H; Norman RB; Hackney LA; Takaoka Y; Mitsuya H
J Mol Biol; 2008 Sep; 381(4):956-74. PubMed ID: 18590744
[TBL] [Abstract][Full Text] [Related]
20. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
